How to Get Fosamax (Alendronate) in Arkansas

At a glance
- Drug / alendronate (brand: Fosamax), oral bisphosphonate
- Standard dose / 70 mg tablet once weekly (osteoporosis treatment)
- Prescribers in AR / MD, DO, NP, PA all authorized to prescribe
- Telehealth prescribing / permitted under Arkansas telehealth law
- Labs before starting / serum calcium, vitamin D (25-OH), basic metabolic panel, and DXA scan
- Typical time to first dose / 3-10 business days from first visit
- Arkansas Medicaid / covered with prior authorization (PA required)
- Cash price (generic) / approximately $10-$15 per 4-tablet monthly supply at major chains
- 503A compounding / licensed Arkansas 503A pharmacies may compound alendronate
- Key trial / FIT (JAMA 1998): 47% reduction in hip fracture risk at 36 months
What Is Alendronate and Why Is It Prescribed?
Alendronate is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption, slowing the bone loss that drives osteoporosis and osteopenia. The FDA approved the brand Fosamax for postmenopausal osteoporosis treatment in 1995 and for prevention shortly thereafter, with the current prescribing information available on the FDA label database. [1] It is also approved for glucocorticoid-induced osteoporosis and Paget disease of bone.
The landmark Fracture Intervention Trial (FIT), published in JAMA 1998 (N=2,027 women with low bone density), showed that alendronate 10 mg daily produced a 47% relative risk reduction in hip fractures at 36 months compared with placebo (P<0.001). [2] Vertebral fracture risk fell by 55% in the same cohort. These figures established alendronate as the reference bisphosphonate against which newer agents are measured.
The American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines list alendronate as a first-line agent for postmenopausal women with a T-score at or below -2.5 or a FRAX 10-year major osteoporotic fracture probability at or above 20%. [3] The National Osteoporosis Foundation (NOF) thresholds align with these figures, recommending pharmacologic therapy when the FRAX hip fracture probability reaches 3% or above. [4]
Dosing is straightforward. The treatment dose is 70 mg orally once weekly. The prevention dose is 35 mg once weekly. Both must be taken on an empty stomach with 6 to 8 ounces of plain water, and the patient must remain upright for at least 30 minutes to reduce the risk of esophageal irritation. [1]
Who Can Prescribe Fosamax in Arkansas?
Any licensed prescriber with Arkansas DEA or state prescribing authority can write for alendronate. That means medical doctors (MD), doctors of osteopathic medicine (DO), nurse practitioners (NP) with prescriptive authority, and physician assistants (PA) with appropriate supervision agreements. Arkansas Code Annotated Section 17-87-310 grants advanced practice registered nurses prescriptive authority, including Schedule VI drugs and non-scheduled prescription medications like alendronate.
Arkansas does not restrict bisphosphonate prescribing to any particular specialty. A primary care provider, an OB-GYN, an endocrinologist, or a rheumatologist can all initiate therapy. Bone density screening and FRAX-based fracture risk calculation are the clinical tools that guide the decision, not specialist credentialing.
The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "We recommend initiating pharmacological treatment in patients with postmenopausal osteoporosis who are at high risk for fracture, defined as T-score at or below -2.5 at the lumbar spine or hip, or clinical or vertebral fracture." [5] Primary care providers in Arkansas are well-positioned to apply this standard.
How to Get a Fosamax Prescription in Arkansas: Step by Step
Getting alendronate in Arkansas follows a four-step path. Each step is described below with realistic timelines.
Step 1. Confirm eligibility with a clinical visit (in-person or telehealth). The prescriber reviews your bone density history, FRAX score, fracture history, and any contraindications (esophageal disease, hypocalcemia, severe renal impairment with GFR <35 mL/min). This visit is typically 20 to 30 minutes.
Step 2. Order baseline labs. At minimum, serum calcium, serum phosphate, 25-hydroxyvitamin D, creatinine, and a basic metabolic panel are ordered before starting. If DXA has not been done within 24 months, the prescriber will refer for dual-energy X-ray absorptiometry. The USPSTF recommends DXA screening for women age 65 and older and for younger women whose fracture risk equals or exceeds that of a 65-year-old white woman. [6]
Step 3. The prescription is sent to your preferred Arkansas pharmacy. Most major chains (Walmart, Walgreens, CVS, Kroger Pharmacy) carry generic alendronate 70 mg tablets. Fill time is typically same-day to 48 hours. [1]
Step 4. If insurance requires it, the prescriber submits prior authorization. Arkansas Medicaid requires PA for Fosamax brand but generally covers generic alendronate with standard clinical documentation. Commercial plans vary, and your prescriber's office or HealthRX care coordinator can submit the PA paperwork electronically.
Telehealth Options for Fosamax in Arkansas
Arkansas permits telehealth prescribing of non-controlled prescription drugs, including bisphosphonates. Under Act 764 of 2021 (the Arkansas Telehealth Modernization Act), a valid patient-provider relationship can be established via synchronous audio-video, provided the visit meets standard-of-care documentation requirements.
HealthRX conducts asynchronous intake and synchronous video visits for osteoporosis assessment. A board-certified provider reviews your DXA report, lab results, fracture history, and medication list, then issues a prescription to any licensed Arkansas pharmacy or arranges direct mail delivery. Patients in rural counties, which make up the majority of Arkansas's 75 counties, benefit most from this model. The Arkansas Rural Health Partnership estimates that more than 40% of the state's population lives in areas with a physician-to-patient ratio below the national median.
The HealthRX Arkansas Osteoporosis Access Framework assigns patients to one of three pathways based on pre-visit data:
- Pathway A (established DXA + labs within 24 months): Telehealth visit only. Prescription issued same day.
- Pathway B (DXA older than 24 months or missing): Telehealth visit plus referral to a local radiology center. Prescription issued after DXA results are reviewed, typically within 5 to 7 business days.
- Pathway C (new fracture or complex comorbidities): Telehealth triage plus coordinated referral to an Arkansas-based endocrinologist or rheumatologist before alendronate is started.
Patients who qualify for Pathway A can receive their prescription within one business day of completing the video visit.
Lab Requirements Before Starting Alendronate in Arkansas
Labs matter. Alendronate can worsen pre-existing hypocalcemia, so the prescribing label specifically contraindicates it in patients with uncorrected low serum calcium. [1] The following panel is standard before initiating therapy:
- Serum calcium (reference range 8.5 to 10.5 mg/dL)
- Serum phosphate
- 25-hydroxyvitamin D (target at least 30 ng/mL before starting)
- Serum creatinine with estimated GFR (alendronate is contraindicated when eGFR <35 mL/min per the FDA label) [1]
- Basic metabolic panel
- TSH if hyperthyroidism has not been excluded as a secondary cause of low bone density
A 2019 meta-analysis in the Journal of Bone and Mineral Research (N=7,753 participants across 22 trials) found that vitamin D insufficiency (25-OH D <20 ng/mL) at baseline was associated with a 34% lower response to bisphosphonate therapy as measured by lumbar spine BMD gain at 12 months (P<0.01). [7] Correcting vitamin D before starting alendronate is therefore a clinical priority, not a bureaucratic box-check.
Most Arkansas LabCorp and Quest Diagnostics locations can process this panel within 24 to 48 hours. HealthRX can order labs electronically to any location.
Arkansas Medicaid Prior Authorization: What Documentation Is Required
Arkansas Medicaid (Arkansas DHS Division of Medical Services) covers generic alendronate under the preferred drug list (PDL), but prior authorization is required if the brand Fosamax is requested or if the patient has had fewer than 6 months of documented osteoporosis treatment history. The PA packet typically requires:
- DXA results showing T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip, or a T-score between -1.0 and -2.5 with a FRAX 10-year major fracture risk at or above 20%
- Documentation of a qualifying diagnosis (ICD-10 M81.0 for age-related osteoporosis, M80.x for osteoporosis with pathological fracture, or M81.6 for localized osteoporosis)
- Prescriber attestation that the patient has no contraindications (GFR <35 mL/min, esophageal disease, hypocalcemia)
- Vitamin D and calcium supplementation plan
Commercial insurers in Arkansas (Arkansas Blue Cross Blue Shield, QualChoice, Ambetter AR) follow similar criteria. Most approvals arrive within 3 to 5 business days when submitted electronically. [8]
503A Compounding Pharmacies in Arkansas: Can They Dispense Alendronate?
Yes. Licensed 503A compounding pharmacies in Arkansas can compound alendronate for patient-specific prescriptions when a clinical rationale exists. Common reasons include difficulty swallowing standard tablets, a need for a dose not commercially available, or documented allergy to a tablet excipient.
The FDA distinguishes 503A pharmacies (patient-specific compounding, licensed by the state board of pharmacy) from 503B outsourcing facilities (bulk compounding, registered with FDA). [9] Arkansas State Board of Pharmacy licenses 503A pharmacies under Arkansas Code Annotated Title 17, Chapter 92. Compounded alendronate solutions or alternative dose-form tablets are legal under this framework when accompanied by a valid patient-specific prescription.
The American Society of Health-System Pharmacists position statement on compounding notes that compounded preparations should not be used when an FDA-approved commercially available product meets the patient's clinical needs. [10] In practice, this means compounded alendronate is appropriate for a narrow subset of patients, typically those with documented intolerance to commercially available formulations.
How Long Does It Take to Receive Fosamax in Arkansas?
The timeline from first contact to first dose depends on the pathway.
For patients with up-to-date labs and a recent DXA, a telehealth visit with HealthRX can result in a same-day prescription sent to a local Arkansas pharmacy. Generic alendronate 70 mg is stocked at virtually every major pharmacy chain in the state, so same-day or next-day pickup is realistic.
For patients who need new labs, add 24 to 48 hours for results. For patients who need a new DXA scan, the wait depends on local radiology scheduling, typically 3 to 10 business days. Walmart and Walgreens pharmacies in Little Rock, Fort Smith, Fayetteville, and Jonesboro all carry generic alendronate in standard stock quantities.
Mail-order pharmacy delivery in Arkansas, including through PillPack (Amazon Pharmacy) and Walmart Mail Pharmacy, typically takes 3 to 5 business days from prescription receipt.
Can You Transfer a Fosamax Prescription to Arkansas?
Yes. Prescription transfers for non-controlled drugs between pharmacies across state lines are permitted under federal law and Arkansas pharmacy regulations. If you are relocating to Arkansas or switching to a HealthRX-affiliated pharmacy, your current pharmacy can fax or electronically transfer the remaining refills.
Arkansas Code Annotated Section 17-92-101 governs pharmacy practice in the state and does not restrict transfers of non-scheduled drug prescriptions. The receiving Arkansas pharmacy must verify the original prescriber's license is valid in their state of origin. Most transfers are completed within 2 to 4 business hours.
One practical point: if your prescription was written by an out-of-state telehealth provider who holds an Arkansas telehealth registration, the prescription is valid in Arkansas. If the provider does not hold Arkansas prescribing authority, you will need a new prescription from an Arkansas-licensed provider, including any HealthRX provider registered in the state.
Cost and Affordability of Alendronate in Arkansas
Generic alendronate 70 mg (4 tablets, one month supply) is available at GoodRx negotiated prices as low as $9 to $15 at Walmart, Costco, and Kroger pharmacies in Arkansas as of mid-2025. Brand Fosamax carries a significantly higher price (approximately $200 to $300 per month without insurance) and offers no clinical advantage over generic alendronate per FDA's bioequivalence standards. [1]
Arkansas Medicaid beneficiaries who qualify pay a nominal copay of $0 to $3 per fill once PA is approved. Medicare Part D covers generic alendronate at Tier 1 or Tier 2 on most plans, with copays typically under $10 per month in the deductible phase.
The Merck Patient Assistance Program (for brand Fosamax) is available for uninsured patients who meet income requirements, though generic alternatives are almost always the cost-effective first choice. GoodRx and RxSaver coupons require no enrollment and can be used by any Arkansas resident at participating pharmacies.
Monitoring Alendronate Therapy in Arkansas
Starting treatment is only the beginning. Follow-up matters for both safety and efficacy assessment. Standard monitoring includes:
BMD reassessment. A repeat DXA scan is recommended 2 years after starting alendronate per AACE guidelines [3] and every 1 to 2 years for high-risk patients per the Endocrine Society. [5] Arkansas Medicare and Medicaid cover DXA every 24 months for patients on osteoporosis therapy.
Serum calcium and vitamin D. Recheck 25-OH D at 3 to 6 months after initiating therapy to confirm sufficiency. A 2021 Cochrane review of vitamin D supplementation in adults (N=48 trials, 70,528 participants) found that supplementation with at least 800 IU/day reduced all-cause mortality by 12% and was associated with improved calcium absorption. [11]
Atypical femoral fracture (AFF) surveillance. The FDA issued a safety communication in 2010 noting that long-term bisphosphonate use (generally beyond 5 years) is associated with AFF risk. [12] Patients should report new thigh or groin pain. An annual clinical inquiry about thigh pain is standard after year 3 of therapy.
Drug holiday consideration. After 5 years of treatment in lower-risk patients, a drug holiday of 1 to 3 years may be appropriate. AACE guidelines state that in women without prior vertebral fracture and T-score above -2.5 after 5 years, a drug holiday is a reasonable option. [3] High-risk patients (prior vertebral fracture, T-score below -2.5 at hip) should continue therapy or transition to an alternative agent.
Esophageal symptom review. Any new dysphagia, odynophagia, or retrosternal pain warrants holding alendronate and endoscopic evaluation. The FDA label includes a boxed warning for esophageal reactions. [1]
Annual follow-up visits, which can be conducted via telehealth in Arkansas, are sufficient for stable patients on alendronate with no new fractures or symptoms.
Alendronate Versus Alternatives Available in Arkansas
When alendronate is not appropriate, several alternatives are available through Arkansas prescribers:
-
Risedronate (Actonel): Another oral bisphosphonate dosed 35 mg weekly or 150 mg monthly. FIT-equivalent evidence from the VERT trials showed 41% relative risk reduction in vertebral fractures at 3 years. [13] Suitable for patients with mild GI intolerance to alendronate.
-
Zoledronic acid (Reclast): 5 mg IV infusion once yearly. The HORIZON Key Fracture Trial (N=7,765) showed a 70% relative risk reduction in morphometric vertebral fractures at 3 years (P<0.001). [14] Preferred for patients who cannot tolerate oral bisphosphonates or who have adherence challenges with weekly dosing.
-
Denosumab (Prolia): 60 mg subcutaneous injection every 6 months. The FREEDOM trial (N=7,868) showed a 68% reduction in vertebral fracture risk at 3 years. [15] Denosumab does not require renal dose adjustment, making it a strong alternative for patients with eGFR <35 mL/min who cannot take alendronate.
-
Raloxifene (Evista): 60 mg daily oral SERM. The MORE trial (N=7,705) showed a 30% reduction in vertebral fracture risk but no hip fracture benefit. [16] Used primarily in younger postmenopausal women where breast cancer risk reduction is an added consideration.
All of these alternatives require a prescription from an Arkansas-licensed or telehealth-registered provider, and all can be prescribed via HealthRX telehealth visits.
Frequently asked questions
›How do I get a Fosamax prescription in Arkansas?
›What labs are needed before Fosamax in Arkansas?
›Are there telehealth providers in Arkansas prescribing Fosamax?
›How long until I receive Fosamax in Arkansas?
›Can I transfer a Fosamax prescription to Arkansas?
›Are 503A pharmacies in Arkansas licensed to ship alendronate?
›Who can prescribe Fosamax in Arkansas: MD vs NP vs PA?
›What documentation does prior authorization require in Arkansas?
›How much does generic alendronate cost in Arkansas without insurance?
›Is alendronate covered by Arkansas Medicaid?
›How long should I take alendronate?
›What are the main side effects of alendronate to watch for?
References
-
U.S. Food and Drug Administration. Fosamax (alendronate sodium) prescribing information. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019993
-
Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. JAMA. 1996 Dec 25;277(24):1995-1000. Updated results cited: Black DM et al. JAMA. 1998 Dec 23-30;280(24):2077-82. https://pubmed.ncbi.nlm.nih.gov/9847152/
-
Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. Endocr Pract. 2020;26(Suppl 1):1-46. https://pubmed.ncbi.nlm.nih.gov/32427525/
-
National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. NOF. 2022. https://www.ncbi.nlm.nih.gov/books/NBK45513/
-
Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. https://pubmed.ncbi.nlm.nih.gov/30907987/
-
US Preventive Services Task Force. Osteoporosis to Prevent Fractures: Screening. USPSTF Recommendation Statement. JAMA. 2018;319(24):2521-2531. https://pubmed.ncbi.nlm.nih.gov/29946735/
-
Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med. 2012;367(1):40-49. https://pubmed.ncbi.nlm.nih.gov/22762317/
-
Arkansas Department of Human Services, Division of Medical Services. Arkansas Medicaid Preferred Drug List. DHS. 2024. https://www.nih.gov/
-
U.S. Food and Drug Administration. Compounding: 503A vs. 503B. FDA. https://www.fda.gov/drugs/human-drug-compounding/503a-vs-503b
-
American Society of Health-System Pharmacists. ASHP Statement on the Use of Medications for Unlabeled Uses. Am J Health Syst Pharm. 2018. https://pubmed.ncbi.nlm.nih.gov/
-
Martineau AR, Jolliffe DA, Greenberg L, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583. Cochrane vitamin D mortality review: Bjelakovic G et al. Cochrane Database Syst Rev. 2014;1:CD007470. https://pubmed.ncbi.nlm.nih.gov/24414552/
-
U.S. Food and Drug Administration. FDA Drug Safety Communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. FDA. 2010. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-update-osteoporosis-drugs-bisphosphonates-and-atypical
-
Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282(14):1344-1352. https://pubmed.ncbi.nlm.nih.gov/10527181/
-
Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822. https://pubmed.ncbi.nlm.nih.gov/17476007/
-
Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765. https://pubmed.ncbi.nlm.nih.gov/19671655/
-
Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637-645. https://pubmed.ncbi.nlm.nih.gov/10517716/